Shionogi, Response Biomedical to Conclude Sales Agreement for Rapid BNP Test.Tokyo, Japan, May 19, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi has concluded a sales agreement with Canadian company Response Medical for the sale of SHIONOSPOT BNP BNP B-type natriuretic peptide, brain natriuretic peptide Physiology A 32-residue peptide hormone produced predominantly in the ventricles, secreted in response to fluid overload–eg, CHF. See Atrial natriuretic peptide. , a point-of-care test reagent, and the SHIONOSPOT Reader in Japan. SHIONOSPOT BNP, which is based on fluorescent immunochromatographic assay, can measure the levels of B-type natriuretic peptide B-type natriuretic peptide See BNP. (BNP) in the blood. BNP is a kind of hormone that reflects deterioration in heart functions. Used in combination with the SHIONOSPOT Reader, the reagent can obtain results in about 16 minutes. Shionogi expects that the launch of SHIONOSPOT will contribute to the diagnosis and management of congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. at clinical sites. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion